Enisamium iodide
Names: Enisamium iodide, Amizon / Amazon (trade name), carbabenzpiride
Recent studies have shown that the antiviral effect of enisamium is due to inhibition of viral RNA polymerase of influenza virus. See Wikipedia for references. The antiviral activity of enisamium iodide is associated with inhibition of influenza virus RNA polymerase. Enisamium iodide effectively inhibited SARS-CoV-2 virus replication in vitro in Caco-2 cells.
Clinical efficacy and safety
In 2010, the third phase of clinical trials on the basis of FBDU "Research Institute of Influenza" of the Ministry of Health of the Russian Federation (St. Petersburg, Russia) was completed with 100 patients (60 patients with influenza and SARS received enisamium iodide, 40 – placebo).
Machine translation of information on Amizon
From https://compendium.com.ua/dec/271524/#toc-6
Storage
Active ingredient: amizon ® (enisamium iodide)
1 tablet contains 125 mg (0.125 g) or 250 mg (0.25 g) of amizone ® (enisamium iodide);
excipients: lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, calcium stearate;
shell: OPADRY II Clear 85F19250 (polyethylene glycol, polysorbate 80, polyvinyl alcohol, talc).
Medicinal form
Coated tablets.
The main physical and chemical properties: round, biconvex, yellow or yellow-green tablets, covered with a shell. On the surface of core tablets, the presence of minor inclusions is allowed.
Pharmacotherapeutic group
Antiviral means for systemic use. Antiviral means of direct action.
ATX code J05A X17.
Pharmacological properties
Mechanism of action
Antiviral effect of enisamium is associated with inhibition of the RNA polymerase of the influenza virus. Enisemium iodide effectively inhibited SARS-CoV-2 virus replication in vitro in Caco-2 cells.
Pharmacodynamics
Enisemium has an antiviral effect against various strains of influenza A virus (H1N1, H3N2, H5N1, H7N9), influenza B virus, respiratory syncytial virus, as well as strains of alpha-coronavirus NL-63 and beta-coronavirus SARS-CoV-2 in vitro.
Enisemium iodide has demonstrated efficacy against influenza A and B strains in in vitro studies using differentiated normal human bronchial epithelial (NHBE) cells, human hepatocellular carcinoma (HepG2) cells, human rhabdomyosarcoma (RD) cells, human colorectal adenocarcinoma cells ( Caco-2). In ferrets as a representative animal model for influenza research: enisemium iodide reduced the shedding time of influenza virus from ferret nasal washes compared to a placebo control group.